Vandetanib in advanced medullary thyroid cancer: Review of adverse event management strategies

Advances in Therapy

Volumn 30, Issue 11, 2013, Pages 945-966

  Grande, Enrique ^a   Kreissl, Michael C ^b,c   Filetti, Sebastiano ^d   Newbold, Kate ^e   Reinisch, Walter ^f   Robert, Caroline ^g   Schlumberger, Martin ^g   Tolstrup, Lærke K ^h   Zamorano, Jose L ^a   Capdevila, Jaume ⁱ  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c KLINIKUM AUGSBURG   (Germany)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h ODENSE UNIVERSITY HOSPITAL   (Denmark)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Adverse effects; Antineoplastic agents adverse effects; Cardiovascular; Dermatology; Medullary thyroid cancer; Medullary thyroid carcinoma; Patient safety; Piperidines therapeutic use; Protein kinase inhibitors; Thyroid neoplasms drug therapy; Vandetanib

Indexed keywords

ALCLOMETASONE; AMMONIUM LACTATE; ANTIHISTAMINIC AGENT; APREPITANT; BIOTIN; CLINDAMYCIN; CORTICOSTEROID; DESONIDE; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXEPIN; DOXYCYCLINE; EMOLLIENT AGENT; FLUTICASONE PROPIONATE; GABAPENTIN; HYDROCORTISONE; LACTIC ACID; LOPERAMIDE; MENTHOL; METHYLPREDNISOLONE; PALONOSETRON; PRAMOCAINE; PREGABALIN; SALICYLIC ACID; SILVER NITRATE; SOMATOSTATIN DERIVATIVE; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG; VANDETANIB; ZINC OXIDE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ADVANCED CANCER; ADVERSE DRUG REACTION; ASTHENIA; BLEEDING; CANCER PATIENT; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONIC DRUG ADMINISTRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; ERYTHEMA MULTIFORME; FINGER MALFORMATION; FOLLICULITIS; GASTROINTESTINAL DISEASE; HEALTH CARE NEED; HUMAN; HYPERKERATOSIS; HYPERTENSION; LOW DRUG DOSE; MEDICAL EDUCATION; MEDICAL EXPERT; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; PARONYCHIA; PATIENT COMPLIANCE; PATIENT MONITORING; PHOTOSENSITIVITY; PRACTICE GUIDELINE; PRURITUS; QT PROLONGATION; REVIEW; RISK ASSESSMENT; SKIN DISEASE; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; STOMATITIS; SYSTEMIC THERAPY; THYROID MEDULLARY CARCINOMA; XEROSIS; CANCER STAGING; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ERUPTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GASTROINTESTINAL DISEASES; MALE; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; PATIENT SELECTION; PROGNOSIS; THYROID NEOPLASMS; TREATMENT OUTCOME; TUMOR INVASION;

CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT SELECTION; PIPERIDINES; PROGNOSIS; QUINAZOLINES; RISK ASSESSMENT; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84890125211     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-013-0069-5     Document Type: Review

References (41)

1. Schlumberger M, Bastholt L, Dralle H, et al. European Thyroid Association guidelines for metastatic medullary thyroid cancer. Eur Thyroid J. 2012;1:5-14.
2. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107:2134-42.
3. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002;62:7284-90.
4. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002;62:4645-55.
5. AstraZeneca 2012. Caprelsa (vandetanib) tablets: US prescribing information. http://www.astrazeneca-us.com/pi/caprelsa.pdf (Accessed Sep 10, 2013).
6. European Medicines Agency (EMA) 2012. Caprelsa (vandetanib): Summary of Product Characteristics, AstraZeneca. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/002315/WC500123555.pdf (Accessed Sep 10, 2013).
7. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30:134-41.
8. Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28:767-72.
9. Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012;13:897-905.
10. Brassard M, Neraud B, Trabado S, et al. Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer. J Clin Endocrinol Metab. 2011;96:2741-9.
11. Langmuir PB, Yver A. Vandetanib for the treatment of thyroid cancer. Clin Pharmacol Ther. 2012;91:71-80.
12. Zang J, Wu S, Tang L, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis. PLoS ONE. 2012;7:e30353.
13. Thornton K, Kim G, Maher VE, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2012;18:3722-30.
14. Martin P, Oliver S, Kennedy SJ, et al. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Clin Ther. 2012;34:221-37.
15. Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2664-71.
16. Rosen AC, Wu S, Damse A, Sherman E, Lacouture ME. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97:1125-33.
17. Giacchero D, Ramacciotti C, Arnault JP, et al. A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol. 2012;148:1418-20.
18. Peuvrel L, Bachmeyer C, Reguiai Z, et al. Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors. Support Care Cancer. 2012;20:909-21.
19. Stahli BE, Schwab S. Amiodarone-induced skin hyperpigmentation. QJM. 2011;104:723-4.
20. Yoon J, Oh CW, Kim CY. Stevens-Johnson syndrome induced by vandetanib. Ann Dermatol. 2011;23:S343-5.
21. Joshi SS, Ortiz S, Witherspoon JN, et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer. 2010;116:3916-23.
22. Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology. 2007;72:152-9.
23. Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19:1079-95.
24. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist. 2007;12:610-21.
25. Lacouture ME, Maitland ML, Segaert S, et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer. 2010;18:509-22.
26. National Cancer Institute 2010. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. http://ctep.cancer.gov/protocolDevelopment/electronic- applications/ctc.htm#ctc-40 (Accessed Nov 22, 2012).
27. Qi WX, Shen Z, Lin F, et al. Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol. 2013;75:919-30.
28. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med. 2012;19:403-88.
29. Isbister GK, Page CB. Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice. Br J Clin Pharmacol. 2013;76:48-57.
30. Chan A, Isbister GK, Kirkpatrick CM, Dufful SB. Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. QJM. 2007;100:609-15.
31. Fazio S, Palmieri EA, Lombardi G, Biondi B. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res. 2004;59:31-50.
32. Arizona Center for Education and Research on Therapeutics (AZERT). CredibleMeds(R) website. http://www.crediblemeds.org/everyone/composite-list- all-qtdrugs (Accessed Sep 10, 2013).
33. Hafermann MJ, Namdar R, Seibold GE, Page RL. Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study. Drug Healthc Patient Saf. 2011;3:53-8.
34. Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol. 2004;15:330-7.
35. European Medicines Agency (EMA) 2010. Aloxi (palonosetron) Summary of Product Characteristics, Helsinn Birex Pharmaceuticals Ltd. http://www.ema. europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000563/ WC500024259.pdf (Accessed Sep 10, 2013).
36. Gonullu G, Demircan S, Demirag MK, Erdem D, Yucel I. Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer. 2012;20:1435-9.
37. Yavas C, Dogan U, Yavas G, Araz M, Ata OY. Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study. Support Care Cancer. 2012;20:2343-7.
38. Rumore MM. Cardiovascular adverse effects of metoclopramide: review of literature. Int J Case Rep Images. 2012;3:1-10.
39. European Medicines Agency (EMA) 2008. Emend (aprepitant) Summary of Product Characteristics, Merck Sharp & Dohme. http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Product-Information/human/000527/WC500026537.pdf (Accessed Sep 10, 2013).
40. Food and Drug Administration (FDA) 2003. Aprepitant FDA Advisory Committee Background Package. http://www.fda.gov/ohrms/dockets/ac/03/briefing/ 3928B1-01-Merck%20Backgrounder.pdf (Accessed Sep 10, 2013).
41. Massicotte MH, Borget I, Broutin S, et al. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo controlled study. J Clin Endocrinol Metab. 2013;98:2401-8.